Lisata Agrees to Acquire Marea With $225 Million of New Capital
Lisata Therapeutics agreed to acquire privately held Marea Therapeutics in a stock-for-stock transaction accompanied by a $225 million private placement. The combined company will prioritize Marea’s cardioendocrine pipeline, including Phase IIb-stage MAR001 or MAR005…
